Sonoma Pharmaceuticals Inc SNOA shares are trading lower by 11.9% to $0.19 Wednesday morning after the company announced a 1-for-20 reverse stock split.
The stock will trade on a split-adjusted basis starting August 30, 2024. This move aims to meet Nasdaq’s $1.00 minimum bid price requirement. As a result, every 20 shares of Sonoma’s common stock will be consolidated into one share, reducing the total outstanding shares from 20 million to 1 million.
No fractional shares will be issued; instead, shareholders will receive cash for any fractions. The authorized shares will also increase from 24 million to 50 million.
Should I Sell My SNOA Stock?
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Sonoma Pharmaceuticals have lost 75.9% year to date. This compares to the average annual return of -66.61%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.
For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.
SNOA has a 52-week high of $1.02 and a 52-week low of $0.12.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
